Please wait a minute...
Journal of ZheJiang University(Medical Science)  2016, Vol. 45 Issue (6): 614-619    DOI: 10.3785/j.issn.1008-9292.2016.11.09
    
Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy
XIA Guangfa1,2, ZHU Juanying2, YUAN Jun2, CAO Bo2, TANG Jie2, CHEN Yiding1
1. Department of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China;
2. Department of Breast Surgery, Jiaxing Maternity and Child Health Care Hospital, Jiaxing 314000, China
Download:   PDF(1107KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To evaluate the efficacy of adjuvant endocrine therapy (AET) in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy (NAC). Methods: One hundred and six patients who presented with hormone receptor (HR)-positive breast cancer at diagnosis and turned to HR-negative after NAC during December 2000 and December 2013 in Jiaxing Maternity and Child Health Care Hospital were retrospectively identified. Kaplan-Meier analysis and log-rank test were used for univariate analyses of factors related to disease free survival (DFS) and overall survival (OS). Multivariate analysis was carried out using the Cox proportional hazards model in patients with DFS and OS. Results: All the patients were categorized into two groups on the basis of the administration of AET:61 AET-administered patients (57.5%) and 45 AET-naïve patients (42.5%). After a median follow-up of 68 months (range 14-103 months), human epidermal growth factor receptor 2 (HER-2) status, initial clinical stage, pathological axillary lymph node status and the use of AET were identified as the variables affecting DFS and OS (all P<0.05). Patients treated with AET had a significantly improved 5-year DFS rate when compared with that without AET (77.1% vs 53.5%,P<0.05). The 5-year OS of AET-administered patients was also better than that of AET-naïve patients (80.9% vs 71.0%,P<0.05). Cox regression analysis showed that AET-administered or not was the independent predictor for 5-year DFS (HR=2.096, 95% CI:1.081-4.065, P<0.05). Conclusion: Patients with HR altered from positive to negative after NAC may still gain benefit from AET.



Key wordsBreast neoplasms/therapy      Breast neoplasms/pathology      Receptors, estrogen      Receptors, progesterone      Chemotherapy, adjuvant/methods      Treatment outcome      Survival rate      Retrospective studies     
Received: 12 February 2016     
CLC:  R737.9  
  R730.5  
Cite this article:

XIA Guangfa, ZHU Juanying, YUAN Jun, CAO Bo, TANG Jie, CHEN Yiding. Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy. Journal of ZheJiang University(Medical Science), 2016, 45(6): 614-619.

URL:

http://www.zjujournals.com/xueshu/med/10.3785/j.issn.1008-9292.2016.11.09     OR     http://www.zjujournals.com/xueshu/med/Y2016/V45/I6/614


新辅助化疗前后激素受体变化的乳腺癌患者辅助内分泌治疗的疗效

目的:探讨接受新辅助化疗后激素受体由阳性转变为阴性的乳腺癌患者接受辅助内分泌治疗的疗效。方法:回顾性分析2000年12月至2013年12月在嘉兴市妇幼保健院接受新辅助化疗后激素受体由阳性转为阴性的乳腺癌患者106例,按照是否接受辅助内分泌治疗分为观察组和对照组,分析辅助内分泌治疗对其预后的影响,采用Kaplan-Meier法进行生存分析,并通过log-rank法比较不同患者的生存差异,使用Cox模型对患者无病存活率、总存活率的影响因素进行多因素回归分析。结果:106例患者中61例(57.5%)使用了辅助内分泌治疗,中位随访时间为68(14~103)个月。人表皮生长因子受体2(HER-2)状态、临床分期、术后腋窝淋巴结状态以及是否接受辅助内分泌治疗与患者5年无病存活率和总存活率显著相关(均P<0.05),观察组患者5年无病存活率和总存活率均高于对照组患者(77.1%与53.5%,80.9%与71.0%,均P<0.05)。Cox多因素回归分析结果显示,是否接受辅助内分泌治疗是患者5年无病存活率的独立预测指标(HR=2.096,95%CI:1.081~4.065,P<0.05)。结论:激素受体在新辅助化疗后由阳性转为阴性的乳腺癌患者仍可从辅助内分泌治疗中获益。


关键词: 乳腺肿瘤/治疗,  乳腺肿瘤/病理学,  受体,  雌激素,  受体,  孕酮,  辅助化疗/方法,  治疗结果,  存活率,  回顾性研究 
[[1]]   BURCOMBE RJ, MAKRIS A, RICHMAN PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer[J]. Br J Cancer, 2005, 92(1):147-155.
[[2]]   HIRATA T, SHIMIZU C, YONEMORI K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer[J]. Br J Cancer, 2009, 101(9):1529-1536.
[[3]]   JAIN V, LANDRY M, LEVINE EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma[J]. Am Surg, 1996, 62(2):162-165.
[[4]]   TACCA O, PENAULT-LLORCA F, ABRIAL C, et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy[J]. Oncologist, 2007, 12(6):636-643.
[[5]]   EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
[[6]]   CONNOR CS, TAWFIK OW, JOYCE AJ, et al. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens[J]. Am J Surg, 2002, 184(4):322-324.
[[7]]   TAUCHER S, RUDAS M, MADER RM, et al. Prognostic markers in breast cancer:the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer[J]. Wien Klin Wochenschr, 2004, 116(1-2):26-31.
[[8]]   MUELLER-HOLZNER E, FINK V, FREDE T, et al. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens:a reliable predictor of HER2 status of the whole tumor[J]. Breast Cancer Res Treat, 2001, 69(1):13-19.
[[9]]   CHEN X, YUAN Y, GU Z, et al. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer:a meta-analysis[J]. Breast Cancer Res Treat, 2012, 134(3):957-967.
[[10]]   ZHANG N, MORAN MS, HUO Q, et al. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy:a meta-analysis[J]. Cancer Invest, 2011, 29(9):594-598.
[[11]]   GOLDHIRSCH A, WOOD WC, COATES AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. gallen international expert consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22(8):1736-1747.
[[12]]   PEROU C M, SØRLIE T, EISEN M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797):747-752.
[[13]]   SØRLIE T, PEROU C M, TIBSHIRANI R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A, 2001, 98(19):10869-10874.
[1] CHEN Gang,ZHANG Ding,YING Yacao,WANG Zhifeng,TAO Wei,ZHU Hao,ZHANG Jingfeng,PENG Zhiyi. Clinical investigation on transarterial chemoembolization with indigenous drug-eluting beads in treatment of unresectable hepatocellular carcinoma[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 44-51.
[2] WU Han,WANG Zhongjin,MING Wenjie,Shuang WANG,DING Meiping. Monitoring time of interictal epileptiform discharges by long-term video EEG in patients with epilepsy[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 30-35.
[3] CAI Cheng,WANG Jianping,ZHONG Zhifeng,DAI Zhihui,WANG Qinghua,DONG Wuzhen,SHI Hongqi,LIU Qingwei,DU Jinlin. Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy[J]. Journal of ZheJiang University(Medical Science), 2017, 46(1): 36-43.
[4] LI Wenbo, DING Gaoheng, LIU Jun, SHI Jie, ZHANG Chao, GAO Qiuming. Operative versus non-operative treatment for three- or four-part proximal humeral fractures in elderly patients: a meta-analysis of randomized controlled trials[J]. Journal of ZheJiang University(Medical Science), 2016, 45(6): 641-647.
[5] HE Bin, CHAI Yanlan, WANG Tao, ZHOU Zhenxing, LIU Zi. Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer[J]. Journal of ZheJiang University(Medical Science), 2016, 45(4): 395-402.
[6] CHEN Xiaohong, XU Yiping, LU Meiping. Clinical characteristics and etiology of children with hypereosinophilia[J]. Journal of ZheJiang University(Medical Science), 2016, 45(3): 292-296.
[7] JIANG Qianqian, ZHULEPIYA Simayi, CHEN Yulan, ZHOU Xiaohuan, ZHANG Xiangyang, XU Xinjuan, YE Hong. Influencing factors of renal function in hypertensive patients with obstructive sleep apnea-hypopnea syndrome[J]. Journal of ZheJiang University(Medical Science), 2016, 45(3): 261-267.
[8] CHEN Siteng, YU Lixin, DENG Wenfeng, MIAO Yun, LIU Rumin, YE Guirong. Characteristics of urinary tract infection in kidney transplant recipients and non-recipient patients[J]. Journal of ZheJiang University(Medical Science), 2016, 45(2): 201-207.
[9] BIAN Wei, GUAN Jichao, XIE Xishao, TONG Jin, ZHANG Xiaohui, SHOU Zhangfei. Effects of interim hemodialysis on survival and clinical outcomes in patients with maintenance peritoneal dialysis[J]. Journal of ZheJiang University(Medical Science), 2016, 45(2): 195-200.
[10] SHEN Haiyan, XU Chengfu, CHEN Chunxiao. Platelet count predicts therapeutic response of infliximab for active Crohn's disease[J]. Journal of ZheJiang University(Medical Science), 2016, 45(1): 81-85.
[11] WANG Jiaochen, WENG Shouxiang, JIN Xiaofen, YU Wenjie, ZHOU Tao, GAN Meifu. Neuroendocrine differentiation and Wilms' tumor protein-1 expression in breast mucinous carcinoma and their significance[J]. Journal of ZheJiang University(Medical Science), 2016, 45(1): 45-50.
[12] SONG Rui-rui, YU Xin-feng, YERFAN·Jiaerken, SUN Jian-zhong, MAO Ying-ying, GUO Yang, CHEN Zhi-cai, ZHANG Min-ming. Cerebral lesions of DWI hyperintensity in patients with subacute stroke assessed by intravoxel incoherent motion technique[J]. Journal of ZheJiang University(Medical Science), 2015, 44(6): 632-637,644.
[13] ZHAI Li-ping, CHEN Zhi-cai, YAN Shen-qiang, ZHONG Gen-long, ZHANG Sheng, XU Meng-jun, LOU Min. Older age is not related to hemorrhagic transformation and favorable outcomes in patients with wake-up ischemic stroke undergoing intravenous thrombolytic therapy[J]. Journal of ZheJiang University(Medical Science), 2015, 44(6): 638-644.
[14] HUANG Xue-cai, YANG Ling-ling. Comparison clinical efficacy of 3% hypertonic saline solution with 20% mannitol in treatment of intracranial hypertension in patients with aneurysmal subarachnoid hemorrhage[J]. Journal of ZheJiang University(Medical Science), 2015, 44(4): 389-395.
[15] QIN Bin, YING Guang-yu, HU Hua, CHEN Gao, ZHANG Jian-min, WANG Lin. Surgical treatment of anterior circulation aneurysms via lateral supraorbital approach[J]. Journal of ZheJiang University(Medical Science), 2015, 44(4): 383-388.